NICE issues early 'no' on RoActemra, Rydapt by Carly Helfand Wednesday, December 6, 2017 Two Swiss pharma giants got some news out of England Tuesday that they weren’t too excited about.
Novartis wins FDA nod for Rydapt, new targeted drug for AML by Eric Palmer Friday, April 28, 2017 Novartis got FDA approval today for Rydapt, its new breakthrough treatment for acute myeloid leukemia (AML), which is expected to generate more than $250 million in annual sales in the next few years.
